Access cutting-edge her2-positive cancer treatment through this clinical trial at a research site in Muncie. Study-provided care at no cost to qualified participants.
Access her2-positive cancer specialists in Muncie at no cost
This study follows strict safety protocols and ethical guidelines
All study-related her2-positive cancer treatment provided free
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastr
Sponsor: AstraZeneca
Check if you qualify for this her2-positive cancer clinical trial in Muncie, IN
If you're searching for her2-positive cancer treatment options in Muncie, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Muncie research site is actively enrolling participants for this clinical trial. You'll receive care from experienced her2-positive cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.